DNLI News and Press, Denali Therapeutics Inc. From 09/04/19

Phase 1b study of DNL151 includes Parkinson’s disease patients with and without a genetic LRRK2 mutation Either DNL151 or DNL201 anticipated to be selected for potential registrational clinical trials in 2020 The Engage Parkinson’s website provides patients, caregivers...

Addus HomeCare (NASDAQ: ADUS ) initiated with Outperform rating at William Blair. More news on: Addus HomeCare Corporation, Denali Therapeutics Inc., Cronos Group Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Denali Therapeutics (NASDAQ: DNLI ): Q2 GAAP EPS of -$0.61 misses by $0.15 . More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2019,...

Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study. DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for peripheral diseases. Denali will receive a $10 million clinical milestone payment ...

Biotech Pulse Biotech shares are up this year, as represented by the Nasdaq Biotechnology Index ( IBB ), which is the industry benchmark, and the S&P Select Biotechnology Index ( XBI ), after a sharp decline in 2018. This is a welcome respite for biotech investors. However, it has not ...

Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases...

Shares of Denali Therapeutics ( DNLI ) have risen by only 5% since its December 2017 IPO was priced at $18 per share. Year to date, the stock is in the red by about 8%. Given my rekindled interest in the Parkinson space and desire to have more names on the radar that could achieve proof of...

The FDA grants Orphan Drug and Rare Pediatric Disease Designation status to Denali Therapeutics' ( DNLI +0.6% ) DNL310 for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome , a rare inherited disorder characterized by a large head, excess fluid in the bra...

DNL310 on track to enter Phase 1/2 clinical study in Hunter Syndrome patients in 2020 DNL310 utilizes Denali’s proprietary blood-brain barrier crossing enzyme transport vehicle (“ETV”) technology Two additional ETV-enabled enzyme replacement programs were advanc...